Drug Information

Drug General Information
Drug ID
D0K9DI
Former ID
DIB008594
Drug Name
GSK-356278
Synonyms
PDE4 inhibitor (oral, depression/anxiety), GlaxoSmithKline
Drug Type
Small molecular drug
Indication Huntington's disease [ICD9: 294.1, 333.4; ICD10:F02.2, G10] Phase 1 [522890]
Company
Glaxosmithkline
Structure
Download
2D MOL

3D MOL
Formula
C21H25N7O2S
Canonical SMILES
CCN1C2=NC=C(C(=C2C=N1)NC3CCOCC3)C4=NN=C(O4)CC5=C(N=C(S5<br />)C)C
InChI
1S/C21H25N7O2S/c1-4-28-20-15(11-23-28)19(25-14-5-7-29-8-6-14)16(10-22-20)21-27-26-18(30-21)9-17-12(2)24-13(3)31-17/h10-11,14H,4-9H2,1-3H3,(H,22,25)
InChIKey
AWDJJMXJUOHGLC-UHFFFAOYSA-N
PubChem Compound ID
10252640
PubChem Substance ID
15255979, 22635492, 41237897, 74919547, 163642558, 198962460, 228525724, 246579009
Target and Pathway
Target(s) Type IV phosphodiesterase Target Info Inhibitor [532759]
CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [532759]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [532759]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
References
Ref 522890ClinicalTrials.gov (NCT01031186) First Time in Human Study. U.S. National Institutes of Health.
Ref 532759GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.